# ARCH Healthcare Fund

> ARCH Healthcare Fund is a VC fund backing Medical, Health Care and Life Science. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 2
- Last investment: Oct 2018
- Lead investor: 0%
- Last updated: Aug 2026

ARCH Healthcare Fund is an investment firm based California.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |
| Medical Device | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series D | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Earlens | Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. Thisrevolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum. | $87M | Series D | Oct 22, 2018 |  |
| Arbor Pharmaceuticals | Arbor Pharmaceuticals, operates as a specialty pharmaceutical company focusing on pediatric medicine. It engages in licensing, developing, and commercializing late-stage products for common pediatric conditions. The company's products include ZINOTIC and ZINOTIC ES, which addresses Acute Otitis Externa; NEOTIC, an otic analgesic agent for thetreatment of pain and inflammation associated with Acute Otitis Media; and XYLAREX for the dietary management of Recurrent Acute Otitis Media. Its products also include Pediaderm HC Complete Kit, which is specifically developed to treat, manage, and protect the skin of children with atopic dermatitis, commonly referred to as eczema. The company markets its products specialty sales forces in the United States. Arbor Pharmaceuticals, was founded in 2006 and is based in Raleigh, North Carolina. | $34.8M | Series B | Nov 11, 2010 |  |

2 of 2 investments shown.

## Co-investors
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Andrew W. Mellon Foundation](https://shizune.co/investors/profile/andrew-w-mellon-foundation) — VC Fund, 1 deal together
- [Baltisches Haus](https://shizune.co/investors/profile/baltisches-haus) — VC Fund, 1 deal together
- [Cochlear](https://shizune.co/investors/profile/cochlear) — VC Fund, 1 deal together
- [Exor Ventures](https://shizune.co/investors/profile/exor-seeds) — VC Fund, 1 deal together
- [Far East Ventures](https://shizune.co/investors/profile/far-east-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does ARCH Healthcare Fund invest in?

ARCH Healthcare Fund invests primarily in Medical, Health Care and Life Science startups, most often at Series B and Series D stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did ARCH Healthcare Fund last invest?

The most recent investment recorded for ARCH Healthcare Fund closed in Oct 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co